Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series

Firas El Chaer; Nobuyoshi Mori; Dimpy Shah; Nora Oliver; Emily Wang; Anna Jan; Vi Doan; Frank Tverdek; Jean Tayar; Ella Ariza-Heredia; Roy F. Chemaly

doi:10.1016/j.antiviral.2016.08.027

Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series

Firas El Chaer, Nobuyoshi Mori, Dimpy Shah, Nora Oliver, Emily Wang, Anna Jan, Vi Doan, Frank Tverdek, Jean Tayar, Ella Ariza-Heredia, Roy F. Chemaly

Houston Methodist

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Cytomegalovirus (CMV) reactivation is a clinically significant complication in hematopoietic stem cell transplant (HCT) recipients. Alternative therapy for multidrug-resistant CMV is limited and often fails. Leflunomide has been used to treat resistant CMV infections, however, data on efficacy, safety, and guidance for therapeutic drug level monitoring are lacking. In this report, we describe 3 HCT recipients with multi-drug resistant CMV infections who received leflunomide as adjuvant and salvage therapy. The therapeutic effect of leflunomide as an anti-CMV agent based on virologic responses and therapeutic drug monitoring were evaluated.

Original language	English (US)
Pages (from-to)	91-96
Number of pages	6
Journal	Antiviral Research
Volume	135
DOIs	https://doi.org/10.1016/j.antiviral.2016.08.027
State	Published - Nov 1 2016

Keywords

Cytomegalovirus
Drug level
Leflunomide
Resistance
Stem cell transplant

ASJC Scopus subject areas

Pharmacology
Virology

Access to Document

10.1016/j.antiviral.2016.08.027

Cite this

El Chaer, F., Mori, N., Shah, D., Oliver, N., Wang, E., Jan, A., Doan, V., Tverdek, F., Tayar, J., Ariza-Heredia, E., & Chemaly, R. F. (2016). Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series. Antiviral Research, 135, 91-96. https://doi.org/10.1016/j.antiviral.2016.08.027

El Chaer, F, Mori, N, Shah, D, Oliver, N, Wang, E, Jan, A, Doan, V, Tverdek, F, Tayar, J, Ariza-Heredia, E & Chemaly, RF 2016, 'Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series', Antiviral Research, vol. 135, pp. 91-96. https://doi.org/10.1016/j.antiviral.2016.08.027

@article{a963b7d100f2432b9cffa6e55dbe8869,

title = "Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series",

abstract = "Cytomegalovirus (CMV) reactivation is a clinically significant complication in hematopoietic stem cell transplant (HCT) recipients. Alternative therapy for multidrug-resistant CMV is limited and often fails. Leflunomide has been used to treat resistant CMV infections, however, data on efficacy, safety, and guidance for therapeutic drug level monitoring are lacking. In this report, we describe 3 HCT recipients with multi-drug resistant CMV infections who received leflunomide as adjuvant and salvage therapy. The therapeutic effect of leflunomide as an anti-CMV agent based on virologic responses and therapeutic drug monitoring were evaluated.",

keywords = "Cytomegalovirus, Drug level, Leflunomide, Resistance, Stem cell transplant",

author = "\{El Chaer\}, Firas and Nobuyoshi Mori and Dimpy Shah and Nora Oliver and Emily Wang and Anna Jan and Vi Doan and Frank Tverdek and Jean Tayar and Ella Ariza-Heredia and Chemaly, \{Roy F.\}",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier B.V.",

year = "2016",

month = nov,

day = "1",

doi = "10.1016/j.antiviral.2016.08.027",

language = "English (US)",

volume = "135",

pages = "91--96",

journal = "Antiviral Research",

issn = "0166-3542",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients

T2 - A case series

AU - El Chaer, Firas

AU - Mori, Nobuyoshi

AU - Shah, Dimpy

AU - Oliver, Nora

AU - Wang, Emily

AU - Jan, Anna

AU - Doan, Vi

AU - Tverdek, Frank

AU - Tayar, Jean

AU - Ariza-Heredia, Ella

AU - Chemaly, Roy F.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Cytomegalovirus (CMV) reactivation is a clinically significant complication in hematopoietic stem cell transplant (HCT) recipients. Alternative therapy for multidrug-resistant CMV is limited and often fails. Leflunomide has been used to treat resistant CMV infections, however, data on efficacy, safety, and guidance for therapeutic drug level monitoring are lacking. In this report, we describe 3 HCT recipients with multi-drug resistant CMV infections who received leflunomide as adjuvant and salvage therapy. The therapeutic effect of leflunomide as an anti-CMV agent based on virologic responses and therapeutic drug monitoring were evaluated.

AB - Cytomegalovirus (CMV) reactivation is a clinically significant complication in hematopoietic stem cell transplant (HCT) recipients. Alternative therapy for multidrug-resistant CMV is limited and often fails. Leflunomide has been used to treat resistant CMV infections, however, data on efficacy, safety, and guidance for therapeutic drug level monitoring are lacking. In this report, we describe 3 HCT recipients with multi-drug resistant CMV infections who received leflunomide as adjuvant and salvage therapy. The therapeutic effect of leflunomide as an anti-CMV agent based on virologic responses and therapeutic drug monitoring were evaluated.

KW - Cytomegalovirus

KW - Drug level

KW - Leflunomide

KW - Resistance

KW - Stem cell transplant

UR - https://www.scopus.com/pages/publications/84991790351

UR - https://www.scopus.com/inward/citedby.url?scp=84991790351&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2016.08.027

DO - 10.1016/j.antiviral.2016.08.027

M3 - Article

C2 - 27594527

AN - SCOPUS:84991790351

SN - 0166-3542

VL - 135

SP - 91

EP - 96

JO - Antiviral Research

JF - Antiviral Research

ER -

Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this